15-Year watch begins for CAR T-Cell therapy recipients
Knowledge-focused
Recruiting now
This study follows about 546 people who have already received a Galapagos CAR T-cell therapy for blood cancers. Researchers will track them for 15 years to check for long-term side effects, how long the treatment lasts in the body, and overall survival. No new treatment is given—…
Phase: PHASE3 • Sponsor: Lakefront Biotherapeutics NV • Aim: Knowledge-focused
Last updated May 26, 2026 10:34 UTC